CN103479821B - Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof - Google Patents
Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof Download PDFInfo
- Publication number
- CN103479821B CN103479821B CN201310425445.XA CN201310425445A CN103479821B CN 103479821 B CN103479821 B CN 103479821B CN 201310425445 A CN201310425445 A CN 201310425445A CN 103479821 B CN103479821 B CN 103479821B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- active component
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 239000008280 blood Substances 0.000 title claims abstract description 41
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 210000003734 kidney Anatomy 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000008901 benefit Effects 0.000 title claims abstract description 14
- 241000218176 Corydalis Species 0.000 claims abstract description 38
- 241000208340 Araliaceae Species 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 20
- 241000222336 Ganoderma Species 0.000 claims abstract description 19
- 241000005787 Cistanche Species 0.000 claims abstract description 18
- 241000190633 Cordyceps Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 239000012567 medical material Substances 0.000 claims description 37
- 238000000605 extraction Methods 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000005325 percolation Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 abstract description 36
- 208000002173 dizziness Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract description 13
- 208000015891 sexual disease Diseases 0.000 abstract description 13
- 238000010792 warming Methods 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 35
- 208000024891 symptom Diseases 0.000 description 18
- 208000011580 syndromic disease Diseases 0.000 description 17
- 239000008187 granular material Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000006188 syrup Substances 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- -1 nipalgin Chemical compound 0.000 description 5
- 208000037921 secondary disease Diseases 0.000 description 5
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 5
- 229940094720 viagra Drugs 0.000 description 5
- 206010011878 Deafness Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010024419 Libido decreased Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000783421 Corydalis saxicola Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000506964 Dichondra repens Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000876833 Emberizinae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 241000123866 Homalomena occulta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001426 cardiotropic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof.This Chinese medicine is prepared from by the raw material comprising following weight portion: Herba Cistanches, Cordyceps, wild ginseng, Radix Pseudostellariae, Rhizoma Homalomenae, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae), Herba Dichodrae, Ganoderma, Fructus Rosae Laevigatae.Be applicable to the dizziness that male sexual disorder because deficiency of kidney-YIN causes and QI and blood deficiency cause.Chinese medicine composition provided by the invention is in the kidney invigorating warming YANG benefit blood, and determined curative effect, effect is better than prior art.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof.
Background technology
Man's sexual activity is a complicated physiological process, will have been come by a series of trained reflex and unconditioned reflex.Sexual activity comprises libido, erection, sexual intercourse, ejaculation and orgasm five links, wherein arbitrary link generation obstacle and when affecting normal sexual function, be namely called male sexual disorder.Male sexual disorder is a commonly encountered diseases, and sickness rate accounts for 10% of adult male.Along with the quickening of modern life rhythm, from the pressure increase of work, family, economic dispatch aspect, the probability that sexual dysfunction occurs male is higher.
Sexual activity due to male is an extremely complicated continuous print evolution, by the combined effect of multiple link such as psychology, nerve, blood vessel, hormone and hemodynamics, it shows multiple links such as libido, erection, insertion, maintenance erection, ejaculation, patient is difficult to the various symptom of difference, the state of an illness is fuzzy, causes therapeutic effect undesirable.
The principle of medication of general therapeutic male sexual disorder is:
1. hyposexuality person caused by chronic genital duct inflammation, based on antibiotic therapy.
2. androgen low SI person is based on androgen treatment.
3. person caused by systemic disease, should make etiological treatment, be aided with androgen, the Comprehensive Treatments such as vitamin.
Above Therapeutic Method is mostly eager for instant success and quick profits, onlys demand and helps meet an urgent need at the moment, and excite change health with hormone, not only long-term treatment effects is not good temporarily, and is harmful to health, long this with row, dependency is produced to medicine, and cures the symptoms, not the disease, healthyly to go from bad to worse.
Such as viagra a kind of can treat various types of sexual impotence according to the good medea of reflection, but its untoward reaction brought is also very serious, and untoward reaction is high: 1, have a headache.Find in clinical trial, occur headache after about having the people of 1% to take medicine, and taking dose is larger stronger.2, dim eyesight.About have the pill taker of 0.3% that of short duration blurred vision can occur, the unreal of blue light is seen in also there will be of having.3, swoon.Blood pressure rapid drawdown may be caused, as taken the medicines such as nitroglycerin simultaneously, often can giddy even fall in a swoon immediately.4, cardiovascular disease is covered.Sexual impotence may be the tendency of heart disease, diabetes or cancer, takes this medicine and may cover the real state of an illness.5, blood pressure reduces.Viagra can cause blood pressure to reduce, and also can reduce blood pressure containing the cardiotropic formulation such as glyceryl trinitrate or nitrate, therefore when viagra is mixed with these medicines, blood pressure can reduce greatly, sometimes may threat to life.7, glaucoma.Ophthalmologist oculist warns, and taking viagra can cause blood pressure drops, but glaucoma patient intraocular pressure is higher, has the people of 3% ~ 5% to occur acute glaucoma, people one can be made blind for night, can not recover original vision even if cure.
8, temporary deafness.FDA reports, viagra can cause deaf, and about 1/3 is temporary deafness.
9, sleep apnea is increased the weight of.Obstructive sleep apnea is because in sleep, throat's soft tissue subsides, the common disease that obstructing airway causes the respiratory arrest of short time and produces.
By theory of Chinese medical science, male sexual disorder is called sexual impotence, occupies an leading position various Syndrome Differentiation System Hitting Viscera is dialectical, wherein suffer from a deficiency of the kidney the most common in numerous typing with stagnation of liver-QI two pattern of syndrome, it is generally acknowledged that excess syndrome is liver, deficiency syndrome, at kidney, first a point deficiency and excess should verify medication again.To the sexual impotence caused because suffering from a deficiency of the kidney, the tcm therapy of application invigorating kidney, promoting blood circulation can obtain better therapeutic effect.
Chinese medicine thinks that the basic of gas is united at kidney in lung spleen.Every seven emotions and the stimulation such as cold and hot, all can affect and gas and pathological changes occurs, no matter therefore diseases caused by exogenous pathogenic factor or internal injury have the pathological phenomenon of gas, thus have the saying of " all diseases resulting from disorder of QI ".Mainly: gas fills then by force, gas is empty at least, and gas is along then putting down, and QI rising in reverse order is then sick.Blood follows in row body, the nutrition whole body.Disease is if any short, sluggish, absurd row.Deficiency of kidney-YIN, except the Etiological being male sexual disorder, also shows as QI and blood deficiency; The performance of the existing deficiency of vital energy, has again the performance of blood deficiency, nourishes and should adopt QI invigorating and blood producing, training fills blood, QI and blood mending.The patients symptomatic of QI and blood deficiency mostly is dizzy dreaminess, lusterless complexion, cold, the dynamic then hyperhidrosis of limbs.It is uncomfortable that QI and blood deficiency belongs to internal organs, and doctor trained in Western medicine conditioning effect is far away less than the good effect of traditional Chinese medical science kidney-replenishing, spleen invigorating benefit blood.
Above two diseases can be after all deficiency of kidney-YIN, easy-to-use Chinese medicine conditioning and treating.
Summary of the invention
The object of this invention is to provide the Chinese medicine composition of a kind of the kidney invigorating benefit blood;
Another object of the present invention is to provide the Chinese medicine composition preparation method of a kind of the kidney invigorating benefit blood.
The object of the invention is by following technical scheme realize:
The Chinese medicine composition of the kidney invigorating benefit blood described in patent of the present invention, it is prepared from by the raw material comprising following weight portion:
Herba Cistanches 40-80 part, Cordyceps 10-30 part, wild ginseng 10-30 part, Radix Pseudostellariae 10-30 part, Rhizoma Homalomenae 30-60 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 10-30 part, Herba Dichodrae 20-50 part, Ganoderma 10-30 part, Fructus Rosae Laevigatae 30-70 part;
Preferably, be prepared from by the raw material comprising following weight portion:
Herba Cistanches 50-70 part, Cordyceps 15-25 part, wild ginseng 15-25 part, Radix Pseudostellariae 15-25 part, Rhizoma Homalomenae 40-50 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 15-25 part, Herba Dichodrae 30-40 part, Ganoderma 15-25 part, Fructus Rosae Laevigatae 40-60 part;
More preferably, be prepared from by the raw material comprising following weight portion:
Herba Cistanches 60 parts, Cordyceps 20 parts, wild ginseng 20 parts, Radix Pseudostellariae 20 parts, Rhizoma Homalomenae 45 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 20 parts, Herba Dichodrae 35 parts, Ganoderma 20 parts, Fructus Rosae Laevigatae 50 parts.
Below crude drug source and the primary efficacy of Chinese medicine preparation of the present invention:
Herba Cistanches: the fleshy stem of the dry zone scale leaf of orobanchaceae plant cistanche Cistanche deserticola Y. C. Ma or Cistanche Tubulosa Cistanche tubulosa (Schrenk) Wight.Kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation.
Cordyceps: for section ergot fungus cordyceps sinensis bacterium Cordyeps sinensis (BerK.) Sace. colonizes in the dry composite body of Stroma on Hepialidae insect larvae and larva corpse.Gan Pingbao lung, for the deficiency of the lung or deficiency of both the lung and kidney.
Wild ginseng: the dry root of the wild product of Araliaceae Radix Ginseng Panax ginseng C. A. Mey..There is effect of tonify deficiency emergency treatment of collapse, strongly invigorating primordial QI.
Radix Pseudostellariae: the dried root of pinkwort Radix Ginseng Pseudostellaria heterophylla (Miq.) Pax ex Pax et hoffm..Strengthening spleen and lung can be mended, supplementing QI for promoting the production of body fluid.
Rhizoma Homalomenae: the dry rhizome of aroid Rhizoma Homalomenae Homalomena occulta (Lour.) Schott.There is the effects such as wind-damp dispelling, relaxing muscles and tendons and activating QI and blood in the collateral, pain relieving, detumescence.Cure mainly rheumatic arthralgia, stomachache, carbuncle skin ulcer swollen etc.
Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae): be the dry Herb of Fumaraceae Corydalis Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) Corydalis saxicola Bunting.Function: heat-clearing and toxic substances removing, dampness removing, stable, dissipating blood stasis for subsidence of swelling, analgesic hemostatic, has antiinflammatory, function of gallbladder promoting, antiviral, sterilization, sedation and analgesia, enhancing immunologic function, antineoplastic action.
Herba Dichodrae: Convolvulaceae Herba Dichodrae belongs to the dry herb of Herba Dichodrae Dichondra repens.Heat clearing away; Dampness removing; Removing toxic substances.
Ganoderma: On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. Ganoderna lucidum (Leyss.ex Fr.) Karst. or Ganoderma Ganoderna sinense Zhao, the dry sporophore of Xu et Zhang.Invigorating QI and tranquilization, replenishing and restoring lung-QI.
Fructus Rosae Laevigatae: the dry mature fruit of rosaceous plant Fructus Rosae Laevigatae Rosa laevigata Michx..Energy controlling nocturnal emission with astringent drugs reducing urination, relieving diarrhea with astringents, for diseases such as insufficiency of the spleen spermatorrhea, the enuresis.
Another aspect of the present invention there is provided the preparation method of Chinese medicine composition active component of the present invention, and the method adopts the EtOH Sonicate of water extraction or 40-90% concentration expressed in percentage by volume, backflow, lixiviate or/and seepage pressure effects.Concrete its preparation method is as follows:
Scheme one: get whole 9 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filters, it is the clear paste of 1.10-1.25 that filtrate is concentrated into relative density at 70-80 DEG C, obtains active component.
Scheme two: get whole 9 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filter, it is the clear paste of 1.05-1.20 that filtrate is concentrated into relative density at 70-80 DEG C, add ethanol, make alcohol content be 40-70%, leave standstill 12-24 hour, filter, when filtrate is concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
Scheme three: get whole 9 taste medical materials, with ethanol ultrasonic extraction 3-4 time, adds medical material gross weight 2-4 50-90% ethanol doubly at every turn, each supersound extraction 2-5 hour, filters, merging filtrate, when being concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
Scheme four: get whole 9 taste medical materials, with 40-80% alcohol reflux 2-3 time, each ethanol consumption be the 4-10 of medical material total amount doubly, extraction time is 1-4 hour, merge extractive liquid, filters, when filtrate is concentrated into 60-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
Scheme five: get whole 9 taste medical materials, add ethanol percolate extraction 3-4 time, add amount of alcohol at every turn and be equivalent to medical material gross weight 1 ~ 2 times, concentration of alcohol is 40% ~ 60% with volume basis, and percolation speed is that effluent per minute accounts for raw material gross weight 0.2% ~ 0.6%, collects percolate, reclaim ethanol, be evaporated to 1 ~ 2 times that is equivalent to medical material gross weight, filter, obtain active component.
Scheme six: get whole 9 taste medical materials, with soaking in Chinese liquor three times, Chinese liquor wine degree is 30-60 degree, and add Chinese liquor amount at every turn and be equivalent to medical material gross weight 2 ~ 3 times, each soak time is 7-10 days, merges soak, obtains active component.
Its effective ingredient and/or pharmaceutically acceptable carrier can be made various common formulations, as medicated wine, tablet, capsule, pill, drop pill, granule, medicinal tea, mixture, syrup, powder etc. by Chinese medicine composition of the present invention together.
Pharmaceutically acceptable carrier of the present invention includes but not limited to following:
Filler: lactose, dextrin, Icing Sugar, calcium sulfate, sucrose, mannitol, microcrystalline Cellulose, glucose, corn starch etc.
Binding agent: starch slurry, pregelatinized Starch, dextrin etc.
Disintegrating agent: starch, carboxymethyl starch sodium, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low replacement-carboxy-propyl cellulose, citric acid, polyoxyethylene sorbitan monoleate etc.
Lubricant: stearic acid, calcium stearate, magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, Polyethylene Glycol, sodium lauryl sulphate, glyceryl monostearate etc.
Wetting agent: distilled water, ethanol etc.
Correctives: sucrose, stevioside, aspartame etc.
Cosolvent: the polyhydric alcohol such as glycerol, sorbitol.
Fluidizer: micropowder silica gel, Pulvis Talci etc.
Antiseptic: benzoic acid, sodium benzoate, sorbic acid and salt thereof, propanoic acid, parabens etc.
Sugar coating material, as sucrose, Pulvis Talci, gelatin, pigment, river wax etc.; Thin film coating material, as stomach dissolution type water, alcohol coating material etc.
Such as, it can be prepared as various common dosage forms by one of following method: medicated wine, granule, syrup, tablet, capsule.
Method 1: granule
Get one of scheme one to scheme five gained active component, add granule and commonly use adjuvant, production method is prepared into the granule of Chinese medicine composition of the present invention routinely.
Above-mentioned granule is commonly used adjuvant and is comprised one of filler, binding agent, lubricant or whole.
Method 2: syrup
Get one of scheme one to scheme five gained active component, add syrup and commonly use adjuvant, production method is prepared into the syrup of Chinese medicine composition of the present invention routinely.
Above-mentioned syrup is commonly used adjuvant and is comprised one of correctives, antiseptic, cosolvent or whole.
Method 3: tablet
Get one of scheme one to scheme five gained active component, add tablet and commonly use adjuvant, production method is prepared into the tablet of Chinese medicine composition of the present invention routinely.
Above-mentioned tablet is commonly used adjuvant and is comprised one of filler, binding agent, disintegrating agent, lubricant or whole.
Method 4: capsule
Get one of scheme one to scheme five gained active component, add capsule and commonly use adjuvant, production method is prepared into the capsule of Chinese medicine composition of the present invention routinely.
Above-mentioned capsule is commonly used adjuvant and is comprised one of filler, fluidizer, disintegrating agent, lubricant or whole.
Method 5: medicated wine
Get scheme six gained soaking in Chinese liquor liquid, subpackage and get final product.
Kidney is the ground that the Kidney-Yin kidney-Yang of human body rises, and has store essential substances, main water, improving inspiration by invigorating kidney-QI, main bone, raw marrow, fills brain, department's audition and two physiological function such as just, therefore claims that the kidney being the origin of congenital constitution.Kidney essense should Feng Zanggu close and do not let out, if sexual overstrain, injure cloudy essence, or heat enters cloudy point, Kidney-Yinly to be robbed, or its dirty the moon wound, thoroughly must and kidney, cloudy essence all can be made to rob wound and cause deficiency of kidney-YIN, thus cause lumbago due to renal deficiency, kidney not store essential substances, cause seminal emission, lingering diarrhea, this is one of cause of disease of male sexual disorder.In addition, deficiency of kidney-YIN also can make that audition is become deaf, vision is not clear, tinnitus dim eyesight, then vertigo and tinnitus, this dizziness caused for QI and blood deficiency.
The applicant, on the basis of research tradition Chinese herbal medicine, through test for many years, have found the good several drugs of the dizzy therapeutic effect that causes the male sexual disorder caused by deficiency of kidney-YIN and QI and blood deficiency and completes the present invention.
In Chinese medicine composition of the present invention, Herba Cistanches the kidney invigorating reinforcing YIN-essence, benefiting essence-blood, foster the five internal organs; Cordyceps the kidney invigorating lung benefiting, adjustment negative and positive; The main tonifying five ZANG-organs of wild ginseng, solid taking off promote the production of body fluid; Radix Pseudostellariae invigorating qi and benefiting blood, promote the production of body fluid, tonifying the spleen and stomach; Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) toxin expelling is stable, enhancing immunologic function; Herba Dichodrae eliminating damp, detoxifying; Ganoderma replenishing and restoring lung-QI; Fructus Rosae Laevigatae is controlled and suffers from a deficiency of the kidney, Rhizoma Homalomenae blood circulation promoting and blood stasis dispelling, makes gas comply with to some extent and no longer float more, the card spontaneous regression of deficiency-heat.All medicines share above, warming and recuperating the kidney-YANG, warm blood vessels, circulation qi-blood-body fluid, and kidney yang kidney qi is sealed and hides, essence is closed firm, improves male sexual disorder.Kidney essense is sufficient, then kidney qi is healthy and vigorous, and kidney can be done strong and light strength is strong, and the state of mind is quick, movable dexterity, and all medicine silks of prescription enter to detain, and plays the effect that qi and blood tonifying, YIN and YANG balancing, the five internal organs are gentle altogether.
The Chinese medicine composition of a kind of the kidney invigorating benefit blood provided by the invention has the following advantages:
1, the present invention has definite curative effect to the male sexual disorder caused because of deficiency of kidney-YIN, and after Drug therapy of the present invention, the patient of 3 routine hyposexualitys, has had and be clearly better; 39 routine Patients with Premature Ejaculations extend the time of normal sexuality; The patient of 11 routine erection disturbance effectively reaches or maintains erection.
2, the present invention obviously can alleviate the clinical symptoms of QI and blood deficiency patient, reduces symptom and Chinese medicine syndrome integral, evident in efficacy, and without obvious adverse reaction, matched group Bazhen Pills of the present invention is compared, and after treatment, there were significant differences for integration, P<0.05.Show that the embodiment of the present invention is compared with Bazhen Pills, the dizziness caused in treatment QI and blood deficiency has more curative effect.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v represents the volume ratio of solution.
embodiment 1: the preparation (scheme one) of granule
Get Herba Cistanches 60g, Cordyceps 20g, wild ginseng 20g, Radix Pseudostellariae 20g, Rhizoma Homalomenae 45g, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 20g, Herba Dichodrae 35g, Ganoderma 20g, Fructus Rosae Laevigatae 50g, extracting in water 3 times, three amount of water are respectively 12 times, 8 times, 6 times of medical material gross weight, and three extraction times are respectively 3 hours, 2 hours, 1 hour, merge extractive liquid, filter, it is the clear paste of 1.10 that filtrate is concentrated into relative density at 80 DEG C, adds cane sugar powder, dextrin, mixing, granulation, dry, granulate, subpackage, to obtain final product.
embodiment 2: the preparation (scheme four) of granule
Get Herba Cistanches 50 parts, Cordyceps 15 parts, wild ginseng 15 parts, Radix Pseudostellariae 15 parts, Rhizoma Homalomenae 40 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 15 parts, Herba Dichodrae 30 parts, Ganoderma 15 parts, Fructus Rosae Laevigatae 40 parts, with 40% alcohol reflux 3 times, each ethanol consumption is respectively 10 times, 8 times, 4 times of medical material total amount, 4 hours, 2 hours, 1 hour respectively extraction time, merge extractive liquid, filter, when filtrate is concentrated into 60 DEG C, relative density is the extractum of 1.25, obtain active component, add lactose, starch, granulation, drying, granulate, subpackage, to obtain final product.
embodiment 3: the preparation (scheme two) of syrup
Get Herba Cistanches 70 parts, Cordyceps 25 parts, wild ginseng 25 parts, Radix Pseudostellariae 25 parts, Rhizoma Homalomenae 50 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 25 parts, Herba Dichodrae 40 parts, Ganoderma 25 parts, Fructus Rosae Laevigatae 60 parts, extracting in water 3 times, three amount of water are equivalent to 12 times of medical material gross weight respectively, 8 times, 6 times, 3 hours respectively each extraction time, 2 hours, 1 hour, merge extractive liquid, filter, it is the clear paste of 1.20 that filtrate is concentrated into relative density at 70 DEG C, add ethanol, alcohol content is made to be 40%, leave standstill 24 hours, filter, when filtrate is concentrated into 80 DEG C, relative density is the extractum of 1.10, add remelt sugar, potassium sorbate, mixing, subpackage, obtain.
embodiment 4: the preparation (scheme five) of syrup
Get Herba Cistanches 40 parts, Cordyceps 10 parts, wild ginseng 10 parts, Radix Pseudostellariae 10 parts, Rhizoma Homalomenae 30 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 10 parts, Herba Dichodrae 20 parts, Ganoderma 10 parts, Fructus Rosae Laevigatae 30 parts, add ethanol percolate extraction 4 times, add amount of alcohol at every turn and be equivalent to medical material gross weight 2 times respectively, 2 times, 1 times, 1 times, four times percolation concentration of alcohol is respectively 60%, 50%, 40%, 40%, four percolation speed be respectively that effluent per minute accounts for raw material gross weight 0.2%, 0.3%, 0.4%, 0.6%, collect percolate, reclaim ethanol, be evaporated to 1 times that is equivalent to medical material gross weight, filter, add glycerol, nipalgin, stevioside, mixing, subpackage, obtain.
embodiment 5: the preparation (scheme three) of tablet
Get Herba Cistanches 80 parts, Cordyceps 30 parts, wild ginseng 30 parts, Radix Pseudostellariae 30 parts, Rhizoma Homalomenae 60 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 30 parts, Herba Dichodrae 50 parts, Ganoderma 30 parts, Fructus Rosae Laevigatae 70 parts, with ethanol ultrasonic extraction 4 times, add medical material gross weight 4 times for four times respectively, 3 times, 2 times, 2 times, four times ultrasonic concentration of alcohol is respectively 90%, 80%, 60%, 50%, four supersound extraction times are respectively 5 hours, 4 hours, 3 hours, 2 hours, extracting liquid filtering, merging filtrate, when being concentrated into 70 DEG C, relative density is the extractum of 1.25, add lactose, Pulvis Talci, mixing, granulate, dry, tabletting, obtain.
embodiment 6: the preparation (scheme two) of tablet
Get Herba Cistanches 60 parts, Cordyceps 10 parts, wild ginseng 15 parts, Radix Pseudostellariae 20 parts, Rhizoma Homalomenae 30 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 15 parts, Herba Dichodrae 35 parts, Ganoderma 10 parts, Fructus Rosae Laevigatae 40 parts, extracting in water 2 times, each amount of water is equivalent to 12 times of medical material gross weight respectively, 10 times, each extraction time is respectively 3 hours, 2 hours, merge extractive liquid, filter, it is the clear paste of 1.05 that filtrate is concentrated into relative density at 80 DEG C, add ethanol, alcohol content is made to be 70%, leave standstill 12 hours, filter, when filtrate is concentrated into 70 DEG C, relative density is the extractum of 1.25, add dextrin, magnesium stearate, microcrystalline Cellulose, mixing, granulate, dry, tabletting, obtain.
embodiment 7: the preparation (scheme four) of capsule
Get Herba Cistanches 80 parts, Cordyceps 25 parts, wild ginseng 20 parts, Radix Pseudostellariae 30 parts, Rhizoma Homalomenae 50 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 20 parts, Herba Dichodrae 50 parts, Ganoderma 25 parts, Fructus Rosae Laevigatae 50 parts, with alcohol reflux 2 times, each concentration of alcohol is respectively 80%, 60%, each ethanol consumption is respectively 10 times, 8 times of medical material total amount, extraction time is respectively 4 hours, 3 hours, merge extractive liquid, filter, when filtrate is concentrated into 80 DEG C, relative density is the extractum of 1.10, add micropowder silica gel, carboxymethyl starch sodium, mixing, granulate, dry, sieve, enter capsule, to obtain final product.
embodiment 8: the preparation (scheme five) of capsule
Get Herba Cistanches 50 parts, Cordyceps 20 parts, wild ginseng 10 parts, Radix Pseudostellariae 15 parts, Rhizoma Homalomenae 45 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 10 parts, Herba Dichodrae 30 parts, Ganoderma 20 parts, Fructus Rosae Laevigatae 30 parts, add ethanol percolate extraction 3 times, add amount of alcohol at every turn and be equivalent to medical material gross weight 2 times, 2 times, 1 times, three times percolation concentration of alcohol is respectively 60%, 50%, 40%, percolation speed is that effluent per minute accounts for raw material gross weight 0.2% ~ 0.6%, collect percolate, reclaim ethanol, be evaporated to 2 times that are equivalent to medical material gross weight, filter, add Polyethylene Glycol, starch, Pulvis Talci, mixing, granulate, dry, sieve, enter capsule, obtain.
embodiment 9: the preparation (scheme six) of medicated wine
Get Herba Cistanches 40 parts, Cordyceps 30 parts, wild ginseng 10 parts, Radix Pseudostellariae 30 parts, Rhizoma Homalomenae 60 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 10 parts, Herba Dichodrae 50 parts, Ganoderma 10 parts, Fructus Rosae Laevigatae 70 parts, with soaking in Chinese liquor three times, Chinese liquor wine degree is 60 degree, add 3 times, 3 times, 2 times that Chinese liquor amount is equivalent to medical material gross weight respectively at every turn, each soak time is respectively 10 days, 10 days, 7 days, merge soak, subpackage, to obtain final product.
clinical treatment is summed up
One, male sexual disorder clinical treatment is summed up
1 enters to organize case foundation: the male sexual disorder patient belonging to deficiency of kidney-YIN
2 medicines
Treatment group: take embodiment 6 tablet, 2 times on the 1st, each 34 weeks is 1 course for the treatment of.
Matched group: VITAMIN C TABLET, 1 0.2g, 2 times on the 1st, the course for the treatment of same treatment group.
3 observed results
3.1 criterion of therapeutical effect
Effective: transference cure or be clearly better;
Effective: symptom alleviates to some extent;
Invalid: symptom is without improvement or increase the weight of.
3.2 therapeutic outcomes are in table 1.
Table 1 liang group comparitive study
| Group | Number of cases | Effective | Effectively | Invalid | Effective percentage |
| Treatment group | 56 | 38 | 15 | 3 | 94.64% |
| Matched group | 40 | 2 | 7 | 31 | 22.50% |
Note: treatment group effective percentage compared with matched group effective percentage, P<0.01.
Table 1 result shows: the embodiment of the present invention has definite curative effect to the male sexual disorder that deficiency of kidney-YIN causes, because some patient is because mental maladjustment causes sexual dysfunction really, after taking placebo, there is Suggestion to psychology, therefore also demonstrate certain curative effect after treatment.If but most patient is without treatment, any effect can not be reached.
Clinical effectiveness shows: after Drug therapy of the present invention, and the patient of 3 routine hyposexualitys, has had and be clearly better; 39 routine Patients with Premature Ejaculations extend the time of normal sexuality; The patient of 11 routine erection disturbance effectively reaches or maintains erection.
Two, dizzy clinical summary is caused to qi-blood deficiency syndrome
1 case selection
1.1 inclusion criterias are with reference to central vertigo diagnostic criteria in " neurological ", and the central vertigo that the disease such as hemorrhage, the occupy-place of cranium causes except head CT or MRI, transcranial doppler TCD points out vertebral-basilar artery blood flow rate obviously to decline.All belong to QIXUELIANGXU type with reference to " new Chinese medicine guideline of clinical investigations syndrome of deficiency of QI, syndrome of deficiency of blood " is dialectical, deficiency of vital energy syndrome main symptom is: breathe hard, weak, Mental fatigue, deficient pulse; Secondary disease is spontaneous perspiration, lazy speech, light red tongue, possesses primary symptom 2 and secondary disease 1 is namely diagnosable.Blood deficiency syndrome primary symptom is pale white complexion or sallow, dizziness and blurred vision, cardiopalmus; Secondary disease is insomnia, numbness in hands, delayed period, amount lack the light or amenorrhea of color, possesses primary symptom 2 and secondary disease 2 is namely diagnosable.
The central vertigo that 1.2 exclusion standards cause except medicine, wound; Merge severe cardiac, lung, renal insufficiency person; To used drug allergy person.
Whole 100 examples of 2 physical data, are divided into two groups at random, and treatment group and each 50 examples of matched group, age, gender comparison no significant difference, have comparability.
3 Therapeutic Method
3.1 matched group Bazhens Pills (Haiwang Jinxiang Chinese Medicine Pharmaceutical Co., Ltd., Fuzhou City), each 1 ball, every day 2 times.
3.2 treatment groups take embodiment 1 granule, 3 times on the one, each 10g.
3.3 equal 14 days of the courses for the treatment of 2 groups were a course for the treatment of, added up curative effect after the course for the treatment of.
4 criterions of therapeutical effect
Doctor trained in Western medicine symptom and sign, Syndrome in TCM marquis: primary symptom by without, light, in, remember 0,2,4,6 point heavily respectively, secondary disease by without, light, in, remember 0,1,2,3 point heavily respectively.Work out with reference to " new Chinese medicine guideline of clinical investigations " standard.
Recovery from illness: symptom, sign disappear or substantially disappear, the minimizing of syndrome total mark is not less than 95%
Effective: symptom, sign are obviously improved, syndrome is not less than 70% integration minimizing
Effective: symptom, sign take a favorable turn, the minimizing of syndrome total mark is not less than 30%
Invalid: not reach above standard person
5 results the results are shown in Table 2, table 3.
Table 2: two groups of Clinical efficacy comparisons (n=60)
| Recovery from illness | Effective | Effectively | Invalid | Total effective rate | |
| Treatment group | 12 | 28 | 17 | 3 | 95.00% △ |
| Matched group | 3 | 17 | 26 | 14 | 76.67% |
Note: compare with matched group, △ P<0.05.
Table 2 result shows: the treatment group effective percentage taking the embodiment of the present invention 1 is 95.06%, far away higher than matched group 76.67%, has outstanding difference P<0.05.
Table 3 liang group patient doctor trained in Western medicine symptom and sign, Chinese medicine syndrome integral compare (
, n=60)
Note: with this group before treatment, * P<0.05; ◆ P<0.01;
Compared with after treatment of control group, △ P<0.05.
Table 3 result shows:
1, before and after the sign for the treatment of group, matched group, tcm syndrome treatment, integration compares all that there were significant differences, after treatment group treatment compared with before treatment after P<0.01, treatment of control group compared with before treatment P<0.05.
2, after treatment, matched group is compared with treatment group, and there were significant differences for integration, P<0.05.Show that the embodiment of the present invention is compared with Bazhen Pills, the dizziness caused in treatment QI and blood deficiency has more curative effect.
Clinical effectiveness shows the clinical symptoms that the present invention obviously can alleviate QI and blood deficiency patient, reduces symptom and Chinese medicine syndrome integral, evident in efficacy, and without obvious adverse reaction.
model case
Korea Spro, man, 24 years old, pre-marital masturbation, time more than one week 2-3 time, sensualness is lived and is unsatisfied with after marriage, about the time mostly is a few minutes, sometimes can self control, the time slightly extends, and once takes LIUWEI DIHUANG WAN, DeGrain.After diagnosing, be kidney-yin deficiency type premature ejaculation, take the embodiment of the present invention 9 medicated wine, each 20ml, every day 2 times, take two weeks, readme symptom makes moderate progress, and can not deliberately control, and the sexual life time is also than slightly long in the past.Continue to take three months, sexual life time man and wife is all satisfied, and conjunction is humorous, recovery from illness.
Chen, female 32 years old, palm of the hand hyperhidrosis, slightly dynamic namely with a face streaming with sweat at ordinary times, usually dizzy, have three, four dizzinesses can not automatic control, faint, defeated Radix Ginseng Glucose Liquid time once medical, invalid, when cinetosis is severe, chocking sensation in the chest and nausea, by Afenca powder relieving fainting.Card belongs to deficient qi and blood, weakened defensive QI, prolonged illness impairment of YANG.Take the embodiment of the present invention 3 syrup, each 20ml, every day 3 times.After taking 14 days, symptom is obviously improved, and perspires and reduces, and dizziness can be controlled, and need not take Western medicine relieving fainting again.
Lee, female, 26 years old, before each menstruation, dizziness can not be stood, and need lie up, on ordinary days shortness of breath and low voice, lusterless complexion, dizzy dreaminess, and light red tongue is white, thready and weak pulse.Card belongs to QI and blood deficiency, should reinforcing the heart nourish blood, warming YANG and invigorating QI, spleen reinforcing of calming the nerves.Take the embodiment of the present invention 8 capsule, each 2, every day 3 times.Take around menstrual period.First time through after take 14 days after, before next menstruation, dizziness is not obvious, slightly dizziness i.e. mistake after slightly having a rest.Adhere to again taking three menstrual cycle, more no longer occur dizziness time in the period, recovery from illness.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. a Chinese medicine composition for the kidney invigorating benefit blood, is characterized in that it is prepared from by the raw material of following weight portion:
Herba Cistanches 40-80 part, Cordyceps 10-30 part, wild ginseng 10-30 part, Radix Pseudostellariae 10-30 part, Rhizoma Homalomenae 30-60 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 10-30 part, Herba Dichodrae 20-50 part, Ganoderma 10-30 part, Fructus Rosae Laevigatae 30-70 part.
2. Chinese medicine composition according to claim 1, is characterized in that it is prepared from by the raw material of following weight portion:
Herba Cistanches 50-70 part, Cordyceps 15-25 part, wild ginseng 15-25 part, Radix Pseudostellariae 15-25 part, Rhizoma Homalomenae 40-50 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 15-25 part, Herba Dichodrae 30-40 part, Ganoderma 15-25 part, Fructus Rosae Laevigatae 40-60 part.
3. Chinese medicine composition according to claim 1, is characterized in that it is prepared from by the raw material of following weight portion:
Herba Cistanches 60 parts, Cordyceps 20 parts, wild ginseng 20 parts, Radix Pseudostellariae 20 parts, Rhizoma Homalomenae 45 parts, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) 20 parts, Herba Dichodrae 35 parts, Ganoderma 20 parts, Fructus Rosae Laevigatae 50 parts.
4., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filters, it is the clear paste of 1.10-1.25 that filtrate is concentrated into relative density at 70-80 DEG C, obtains active component.
5., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filter, it is the clear paste of 1.05-1.20 that filtrate is concentrated into relative density at 70-80 DEG C, add ethanol, make alcohol content be 40-70%, leave standstill 12-24 hour, filter, when filtrate is concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
6., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, with ethanol ultrasonic extraction 3-4 time, add medical material gross weight 2-4 50-90% ethanol doubly at every turn, each supersound extraction 2-5 hour, filters, merging filtrate, when being concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
7., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, with 40-80% alcohol reflux 2-3 time, each ethanol consumption be the 4-10 of medical material total amount doubly, extraction time is 1-4 hour, merge extractive liquid, filters, when filtrate is concentrated into 60-80 DEG C, relative density is the extractum of 1.10-1.25, obtains active component.
8., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, add ethanol percolate extraction 3-4 time, add amount of alcohol at every turn and be equivalent to medical material gross weight 1 ~ 2 times, concentration of alcohol is 40% ~ 60% with volume basis, and percolation speed is that effluent per minute accounts for raw material gross weight 0.2% ~ 0.6%, collects percolate, reclaim ethanol, be evaporated to 1 ~ 2 times that is equivalent to medical material gross weight, filter, obtain active component.
9., according to the Chinese medicine composition of claim 1-3 described in any one, it is characterized in that its active component is prepared from by the following method:
Get whole 9 taste medical materials, with soaking in Chinese liquor three times, Chinese liquor wine degree is 30-60 degree, and add Chinese liquor amount at every turn and be equivalent to medical material gross weight 2 ~ 3 times, each soak time is 7-10 days, merges soak, obtains active component.
10. a Chinese medicine preparation for the kidney invigorating benefit blood, Chinese medicine composition and the pharmaceutically acceptable carrier combination of the kidney invigorating benefit blood any one of claims 1 to 3 are prepared from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310425445.XA CN103479821B (en) | 2013-09-18 | 2013-09-18 | Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310425445.XA CN103479821B (en) | 2013-09-18 | 2013-09-18 | Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479821A CN103479821A (en) | 2014-01-01 |
| CN103479821B true CN103479821B (en) | 2015-08-19 |
Family
ID=49820634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310425445.XA Expired - Fee Related CN103479821B (en) | 2013-09-18 | 2013-09-18 | Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479821B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000157A (en) * | 2010-11-03 | 2011-04-06 | 张帅 | Medicinal liquor with treatment and health-care functions |
-
2013
- 2013-09-18 CN CN201310425445.XA patent/CN103479821B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000157A (en) * | 2010-11-03 | 2011-04-06 | 张帅 | Medicinal liquor with treatment and health-care functions |
Non-Patent Citations (1)
| Title |
|---|
| 滋肝肾消抗汤治疗抗精子抗体188例;马存亮;《陕西中医》;20041231;第25卷(第6期);512-513 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479821A (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101391077B (en) | Preparation method of traditional Chinese medicine for treating chronic pelvic inflammatory disease | |
| CN101254272A (en) | Promoting coronary circulation and embolism resistance medicament | |
| CN103877247A (en) | Medicine for treating bedsore and preparation method thereof | |
| CN103495055A (en) | Traditional Chinese medicine decoction for treating female endocrine disorders and preparation method thereof | |
| CN101804110B (en) | Traditional Chinese medicine preparation for thrombosis and blood lipid | |
| CN1319403A (en) | Medicine for treating allergic purpura | |
| CN104274754A (en) | Traditional Chinese medicine composition for treating infantile enuresis and preparation method of traditional Chinese medicine composition | |
| CN101695527B (en) | Toxin-expelling intestine-moistening Chinese medicinal preparation and preparation method thereof | |
| CN103251878B (en) | Anti-fatigue traditional Chinese medicine composition | |
| CN101675983A (en) | Warming and tonifying agent for qi-deficiency syndrome | |
| CN103977092A (en) | Medicine composition for treating myocardial infarction and cerebral infarction | |
| CN103920102A (en) | Traditional Chinese medicine for treating primary hypotension | |
| CN103006980A (en) | Chinese medicinal composition for treating distention and fullness | |
| CN103479821B (en) | Chinese medicine composition of a kind of the kidney invigorating benefit blood and preparation method thereof | |
| CN107260978B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method and application thereof | |
| CN103961578A (en) | Traditional Chinese medicine medicinal liquor for treating neurasthenia | |
| CN102743440A (en) | Traditional Chinese medicines for treating femoral head necrosis | |
| CN100571749C (en) | A kind of Chinese medicine preparation for the treatment of sexual impotence | |
| CN105943639A (en) | Traditional Chinese medicine composition assisting in treating chronic subdural hematoma | |
| CN104887949B (en) | A kind of Chinese medicine preparation for the treatment of DCM (dilated cardiomyopathy) and preparation method thereof | |
| CN104645244A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN105031503A (en) | Traditional Chinese medicine preparation for treating hypertension | |
| CN104173995A (en) | Traditional Chinese medicine preparation for treating dysmenorrhea | |
| CN104027766A (en) | Traditional Chinese medicine composition for treating uraemia | |
| CN104274755A (en) | Traditional Chinese medicine preparation for treating infantile enuresis and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140101 Assignee: Yulin honest Chinese Herbal Medicine Co.,Ltd. Assignor: Feng Risheng Contract record no.: 2018450000013 Denomination of invention: Kidney tonifying and blood benefiting traditional Chinese medicine composite and preparation method thereof Granted publication date: 20150819 License type: Common License Record date: 20180424 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |